Payment overview · 2025
General Payments
$522.37
18 reported records · 10 companies
Healthcare provider profile · identity verified
Van Millin, DO
Allopathic & Osteopathic Physicians|Family Medicine · LAGRANGE, GA · NPI 1275682247
Verified facts
What the public records show
CMS Open Payments records show Van Millin, DO received $522.37 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $128.83 | 24.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $90.00 | 17.2% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.06 | 12.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.78 | 11.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.31 | 10.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.36 | 6.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.06 | 5.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.93 | 4.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.63 | 4.5% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $14.41 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $432.37 | 17 |
| Education | $90.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $90.69 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $67.06 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $52.31 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $38.14 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $37.36 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.36 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.36 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 383 | 133 |
| Atorvastatin Calcium | Atorvastatin Calcium | 354 | 133 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 261 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 251 | 90 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 215 | 74 |
| Omeprazole | Omeprazole | 215 | 69 |
| Trazodone Hcl | Trazodone Hcl | 186 | 54 |
| Tramadol Hcl | Tramadol Hcl | 180 | 72 |
| Meloxicam | Meloxicam | 175 | 61 |
| Prednisone | Prednisone | 170 | 116 |
| Pantoprazole Sodium | Pantoprazole Sodium | 167 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 158 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 156 | 55 |
| Ipratropium Bromide | Ipratropium Bromide | 152 | 89 |
| Celecoxib | Celecoxib | 144 | 52 |
| Pregabalin | Pregabalin | 135 | 41 |
| Potassium Chloride | Potassium Chloride | 127 | 45 |
| Lisinopril | Lisinopril | 122 | 48 |
| Furosemide | Furosemide | 119 | 45 |
| Ibuprofen | Ibuprofen | 118 | 44 |
| Fluconazole | Fluconazole | 111 | 53 |
| Etodolac | Etodolac | 109 | 39 |
| Losartan Potassium | Losartan Potassium | 108 | 39 |
| Clonazepam | Clonazepam | 107 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 102 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 33 |
| Alprazolam | Alprazolam | 90 | 17 |
| Ozempic | Semaglutide | 87 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 82 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 81 | 35 |
| Azithromycin | Azithromycin | 80 | 60 |
| Carvedilol | Carvedilol | 80 | 26 |
| Metformin Hcl | Metformin Hcl | 79 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 24 |
| Buspirone Hcl | Buspirone Hcl | 77 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 77 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 34 |
| Atenolol | Atenolol | 72 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 70 | suppressed |
| Simvastatin | Simvastatin | 67 | 26 |
| Allopurinol | Allopurinol | 63 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 20 |
| Montelukast Sodium | Montelukast Sodium | 62 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 61 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 23 |
| Metformin Hcl Er | Metformin Hcl | 53 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 40 |
| Linzess | Linaclotide | 51 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | suppressed |
| Glipizide Er | Glipizide | 50 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 13 |
| Eliquis | Apixaban | 46 | 12 |
| Glipizide | Glipizide | 46 | 20 |
| Sucralfate | Sucralfate | 46 | 12 |
| Famotidine | Famotidine | 45 | 18 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Amoxicillin | Amoxicillin | 40 | 37 |
| Nystatin | Nystatin | 40 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Methocarbamol | Methocarbamol | 35 | 21 |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 15 |
| Farxiga | Dapagliflozin Propanediol | 32 | 14 |
| Bupropion Xl | Bupropion Hcl | 29 | 12 |
| Torsemide | Torsemide | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | 11 |
| Estradiol | Estradiol | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 18 |
| Estradiol (Once Weekly) | Estradiol | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 20 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Cartia Xt | Diltiazem Hcl | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Clarithromycin | Clarithromycin | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Veozah | Fezolinetant | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $522.37 · 18 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BEYFORTUS, CAPLYTA, FARXIGA, FREESTYLE LIBRE 3, Kerendia, Ozempic, PURIFIED CORTROPHIN GEL, Rybelsus, Symbravo, UBRELVY, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error